Promoted Content

Promoted Content

All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Pipeline Developments & Deals by Ellodi Pharmaceuticals

All Data

Filters

refresh

×

FILTER DATA :

Therapeutic Area

Study Phase

Country

News Type

Company

refresh

Companies By Therapeutic Area

Development Status

Ellodi Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

CPhI India 2021

Participation Not Confirmed

Update your events

Ellodi Pharmaceuticals Presents Phase 2b Data at ACG 2020 on the Safety and Efficacy of Maintenance Treatment Following Induction of Remissi...

Contact the Supplier

Lead Product(s): Fluticasone Propionate

Therapeutic Area: Gastroenterology Product Name: APT-1011

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2020

Details:

All APT-1011 dose arms showed clinically meaningful and statistically significant achievement of histological remission with reduction of eosinophil counts in the esophageal mucosa, compared to placebo, at 12 weeks.